Beyond chemotherapy and checkpoint inhibitors: Weighing the risks and benefits of the novel therapies for metastatic urothelial carcinoma Correspondence

  

Authors:	Powles, T.; Petrylak, D. P.; Rosenberg, J. E.
Title:	Beyond chemotherapy and checkpoint inhibitors: Weighing the risks and benefits of the novel therapies for metastatic urothelial carcinoma
Keywords:	cancer chemotherapy; overall survival; drug efficacy; drug safety; follow up; letter; peripheral neuropathy; risk factor; hyperglycemia; transitional cell carcinoma; programmed death 1 ligand 1; programmed death 1 receptor; immune checkpoint inhibitor; human; enfortumab vedotin
Journal Title:	Journal of Clinical Oncology
Volume:	39
Issue:	30
ISSN:	0732-183X
Publisher:	American Society of Clinical Oncology
Date Published:	2021-10-20
Start Page:	3411
End Page:	3412
Language:	English
DOI:	10.1200/jco.21.01430
PROVIDER:	scopus
PUBMED:	34491780
DOI/URL:	https://www.scopus.com/inward/record.uri?eid=2-s2.0-85118303717&doi=10.1200%2fJCO.21.01430&partnerID=40&md5=69b7f03a477cb8ae6c3a9d85eccda443
Notes:	Letter -- Export Date: 1 December 2021 -- Source: Scopus

https://synapse.mskcc.org/synapse/works/has_related_data_chk/190435